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Abstract
Objective
To investigate whether spinal radiographic progression relates to structural damage at the
sacroiliac level in axial spondyloarthritis (axSpA).
Methods
Patients classified as nonradiographic (nr-) and radiographic (r-) axSpA in the Swiss Clinical
Quality Management cohort with radiographs performed every 2 years, scored according to
the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), were included. The
relationship between classification status and spinal progression during 2 years was investi-
gated using binomial generalized estimating equations models with adjustment for sex,
ankylosing spondylitis disease activity score (ASDAS) and tumour necrosis factor inhibitor
treatment. Baseline spinal damage was considered an intermediate variable and included in
sensitivity analyses.
Results
In total, 88 nr-axSpA and 418 r-axSpA patients contributed to data for 725 radiographic
intervals. R-axSpA patients were more frequently male, had a longer disease duration and
higher structural damage at baseline. Mean (SD) mSASSS change over 2 years was 0.16
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(0.62) units in nr-axSpA and 0.92 (2.78) units in r-axSpA, p = 0.01. Nr-axSpA was associ-
ated with a significantly lower progression in 2 years (defined as an increase in�2 mSASSS
units) in adjusted analyses (OR 0.33, 95%CI 0.13; 0.83), confirmed with progression defined
as the formation of�1 syndesmophyte. Mediation analyses revealed that sacroiliitis exerted
its effect on spinal progression indirectly by being associated with the appearance of a first
syndesmophyte (OR 0.09, 95%CI 0.02; 0.36 for nr-axSpA vs r-axSpA). Baseline syndesmo-
phytes were predictors of further progression.
Conclusion
Spinal structural damage is mainly restricted to patients with r-axSpA, leading to relevant
prognostic and therapeutic implications.
Introduction
Functional limitation of the spine in axial spondyloarthritis (axSpA) is the consequence of
both disease activity and accumulated spinal structural damage [1, 2]. The latter is captured
best with the modified Stokes Ankylosing Spondylitis Spine Score (mSASSS) [3], a scoring
method that has been shown to be sensitive to change, including the early phases of the disease
[4]. Prior spinal structural damage seems to be the most important predictor of further damage
in established ankylosing spondylitis [5], now called radiographic (r-) axSpA [6], with mean
progression rates of 1–2 mSASSS units over 2 years [7–9]. Male sex, increased acute phase
reactants, HLA-B27 positivity, as well as smoking predicted spinal progression in some, but
not all investigations [9, 10]. Evidence is accumulating from observational studies that tumour
necrosis factor inhibitors (TNFi) might retard spinal damage, if treatment is continued for
several years [11–14]. Very limited data on spinal radiographic progression exists for the non-
radiographic disease form (nr-axSpA) [4, 10], an entity differentiated from r-axSpA by the
absence of definite sacroiliac damage on radiographs [15, 16], according to the modified New
York criteria (mNYc) [5], but presenting from a clinical point of view, a burden of disease
comparable to r-axSpA despite lower spinal structural damage [17–23]. It remains, however,
unclear whether radiographic sacroiliitis is by itself associated with progression of spinal struc-
tural damage. From a conceptual point of view, a direct association would be present if, for
example, a decreased mobility of the sacroiliac joint could affect physical strain on spinal level
to be able to have an impact on syndesmophyte formation [24]. An indirect association would
occur if—from the perspective of localization—osteoproliferation would primarily affect the
sacroiliac joints and would only later affect the spine. In this case, syndesmophytes would pre-
dominantly occur in patients already presenting with sacroiliac damage. Alternatively, both
direct and indirect pathways might contribute to the association between sacroiliac and spinal
structural damage. Finally, spinal osteoproliferation might be completely disconnected from
structural damage at the level of the sacroiliac joints. This would occur if the mechanisms of
damage were different at the two locations (for example predominantly erosive disease in the
sacroiliac joints and exclusively osteoproliferation at the level of the spine). This does not cor-
respond, however, to the current radiographic and histological data available, as erosive dam-
age followed by putatively reparative osteoproliferation is occurring at both locations of the
axial skeleton [25, 26].
The major objective of this study was to compare spinal radiographic progression in nr-
axSpA versus r-axSpA in a large observational cohort over a period of 2 years and to investigate
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whether spinal progression directly or indirectly relates to sacroiliac structural damage by
means of statistical mediation analyses.
Methods
Study population
Patients with a clinical diagnosis of axSpA recruited into the Swiss Clinical Quality Manage-
ment (SCQM) cohort [19] between January 2005 and August 2016 were included if they ful-
filled the Assessment in SpondyloArthritis international Society (ASAS) 2009 classification
criteria for axSpA [27], if they had an available pelvis radiograph to allow for classification as
nr-axSpA versus r-axSpA [5] and if they also had at least two sets of spinal radiographs, with a
required interval between the radiographs of 2 years ± 1 year. Patients could contribute to sev-
eral intervals. Information on extent and frequency of clinical assessments has been published
previously [19]. Ethics approval was received from the Ethics Committee of the Kanton of
Zurich (KEK-ZH-Nr. 2014–0439, amendment BASEC-Nr. PB_2017–00215). Written informed
consent for data collection was obtained from all patients prior to recruitment into SCQM.
Scoring of radiographs
Reading of pelvis radiographs for changes in the sacroiliac joints was performed in a blinded
manner centrally by 2 members of the SCQM axSpA scientific board according to the mNYc
[5]. In case of discrepancies between the two readers with regard to classification status, the
respective pelvis radiographs were independently scored by an independent adjudicator (AC).
Reading of all spinal radiographs according to the mSASSS [3] was performed by 2 trained
readers (XB and MdH) independently [13]. According to this score, the anterior vertebral
corners (VCs) of the cervical and lumbar spine are scored in the lateral view for the presence
of erosion and/or sclerosis and/or squaring (1 point), syndesmophyte (2 points) and bridging
syndesmophyte (3 points) with a total score per patient ranging from 0 to 72. Radiograph sets
with a total mSASSS score of�71 were excluded, as no further progression of at least 2 units
per 2 years would be possible (N = 8). The readers were blinded to all other information
(including class membership to nr- or r-axSpA), but knew the chronological sequence of
radiographs, as this is more sensitive to change [28]. Only scores of radiographs with�3
missing VC per cervical and lumbar segment were used. Individual missing VCs were imputed
using an adaptation algorithm: first, a missing value for a VC was replaced with the value of
the previous observation. Second, the mean spinal segment’s progression score (either cervical
or lumbar) per patient was calculated. This segmental progression score was added to the
imputed value. In a case of a score missing in a patient with a score of 0 in the same VC at a
subsequent time point, the score of 0 for the previous time point(s) was assumed. If the base-
line score of a VC was missing, the same procedure was applied, subtracting the mean segment
progression from the score of year 3 for a particular patient. If a value of this VC was also miss-
ing at year 2, then the average of the other available VCs from this spinal segment at baseline
was used to replace the missing VC(s). An independent adjudicator (AC) scored all of the
radiographs from patients with an absolute difference in mSASSS status scores between the
primary readers of�5 units in at least one radiograph set. Averaged scores per VC were used
and, in case of adjudication, the score of the primary reader closest to the adjudicator.
We defined radiographic progression as an increase in mSASSS of�2 units over an interval
of 2 years [29]. We also assessed the proportion of patients with formation of�1 new syndes-
mophyte over the same period. Syndesmophytes were only counted if both readers agreed
upon their presence.
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Statistical analyses
We assessed reliability between the two readers for spinal radiograph scoring by a Bland-Alt-
man plot on 2-year progression intervals of mSASSS. In addition, we calculated the smallest
detectable change for 2-year progression scores and the intraclass correlation coefficient on
mSASSS change scores (ICC; type 2, k).
The relationship between classification status as nr-axSpA versus r-axSpA and spinal
radiographic progression over time was investigated using binomial generalized estimating
equations (GEE). These models account for repeated measurements within a patient. An
“exchangeable” correlation structure was used, as we assumed that each patient, given all
covariates, had an individual constant level of radiographic progression probability for all time
points and according to sensitivity analyses of alternative correlation structures in GEE models
in our previously published manuscript on radiographic progression in r-axSpA [13]. Progres-
sion of�2 mSASSS units over 2 years was modelled by using the binomial family and the
logistic link function. Based on our previous analysis in r-axSpA [13], the GEE analyses were
adjusted for sex, ankylosing spondylitis disease activity score (ASDAS), treatment with TNFi
before the respective radiographic interval and the duration of the radiographic interval to
account for differences in interval lengths. ASDAS was chosen over BASDAI and CRP as a
marker of disease activity in the models for its better association with radiographic progres-
sion. Importantly, baseline spinal damage was not included a priori in the main models, as
axSpA classification status might have an effect on baseline spinal damage (indirect relational
pathway). In this case, baseline spinal damage might act as an intermediate variable and should
not be considered in the model to assess the total (direct and indirect) effect of radiographic
sacroiliitis on spinal radiographic progression (Fig 1). It was, however, added to the model in
sensitivity analyses to investigate a potential direct effect of radiographic sacroiliitis on spinal
progression (Fig 1). The indirect association (definite radiographic sacroiliitis present before
Fig 1. Potential impact of radiographic sacroiliitis on spinal progression. The diagram represents the putative effect of radiographic sacroiliitis (X) on
spinal radiographic progression (Y), either directly or indirectly via affecting the baseline presence of syndesmophytes (mediator, M).
https://doi.org/10.1371/journal.pone.0230268.g001
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the appearance of a first syndesmophyte) was tested with the Sobel test with second-order esti-
mator of the standard error, as described by Hayes [30].
Missing baseline covariates were imputed using multiple imputation and models were
averaged using Rubin’s rule. Out of 725 intervals, 123 (17%) had a missing ASDAS value. The
ASDAS was derived by passive imputation. The same GEE model was also fitted using the sub-
set population with complete data sets to assess the robustness of the results. Additional GEE
models were created to also adjust for disease duration, HLA-B27, smoking, physical exercise,
treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), BMI, and the presence of
peripheral arthritis [13]. R statistical software (R Development Core Team, 2011) was used for
all analyses.
Results
Baseline characteristics
Inclusion criterial were fulfilled by 506 axSpA patients (418 r-axSpA and 88 nr-axSpA with�1
radiographic intervals). Demographic and clinical characteristics of these patients at baseline
are presented in Table 1. The prevalence of factors associated with spinal radiographic progres-
sion was higher in patients with r-axSpA, such as male predominance, higher baseline radio-
graphic damage and longer disease duration. Moreover, a higher proportion of patients with r-
axSpA was already treated with TNFi at baseline. However, disease activity as assessed by the
ASDAS was comparable between the two groups.
Baseline characteristics of patients with available radiographs were comparable to those of
all r-axSpA and nr-axSpA patients included in the SCQM cohort (Table 2).
Changes in mSASSS
Interobserver agreement with regard to change in mSASSS was good (ICC 0.85). The smallest
detectable change of radiographic progression during a X-ray interval was 1.85 mSASSS units.
Around 70% of patients in both groups presented with only one radiographic 2-year interval,
20% with 2 intervals and 10% with 3–4 intervals (Table 1). The unadjusted mean (SD) change
in the mSASSS over a period of 2 years was significantly lower in patients with nr-axSpA than
in patients with r-axSpA (0.16 (0.62) versus 0.92 (2.78) mSASSS units, respectively, p = 0.01).
This difference in unadjusted radiographic progression between nr-axSpA and r-axSpA is
shown at the patient level in relation to time since symptom onset in Fig 2. The data is also
depicted at the level of radiographic intervals in cumulative probability plots in Fig 3.
We next evaluated progression in early versus late disease, defined by a cut-off of 5 years of
symptom duration. Mean (SD) spinal progression over 2 years in patients with r-axSpA was
lower in early disease than in late disease (0.29 (1.0) units (71 patients (17%), 86 intervals) ver-
sus 1.07 (3.0) units (361 patients, 519 intervals) respectively, p = 0.02. In contrast, mean (SD)
2-year progression in nr-axSpA was similar in patients with short and longer symptom dura-
tion (0.24 (0.74) units (37 patients (42%), 43 intervals) and 0.10 (0.52) units (52 patients, 66
radiographic intervals), respectively, p = 0.89. A trend for lower radiographic progression was
observed in patients with nr-axSpA already on TNFi at the start of the radiographic interval
(mean progression of 0.02 (0.55) mSASSS units) in comparison to TNFi-naive nr-axSpA
patients (0.21 (0.64) mSASSS units; p = 0.18).
Adjusted longitudinal analyses were performed in 725 radiographic intervals from 506
patients to estimate the joint (direct and/or indirect) effect of sacroiliac damage on spinal pro-
gression. After adjustment for the observed differences in prognostic factors for radiographic
progression in nr-axSpA and r-axSpA, a significantly lower odds for mSASSS progression was
found for nr-axSpA versus r-axSpA (OR 0.33, 95% CI 0.13; 0.83) (Table 3A). The robustness of
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the analysis was confirmed in a complete case analysis (Table 4). Comparable results were
obtained after additional adjustment for disease duration, HLA-B27, smoking status, BMI,
physical exercise, presence of peripheral arthritis, treatment with NSAIDs (OR 0.10, 95% CI
0.01; 0.70; Table 5). The direct effect of sacroiliac damage on spinal radiographic damage,
assessed by introducing baseline mSASSS in the main model, was, however, not significant
(Table 3C). Previous use of TNFi was associated with reduced radiographic progression (OR
0.55, 95% CI 0.34; 0.90), if ASDAS as an intermediate variable for this analysis was removed
from the latter model, confirming results found in our previous investigation of the isolated r-
axSpA subgroup [13].
Table 1. Baseline characteristics at first radiograph.
Parameter N 506 All patients N = 506 nr-axSpA N = 88 r-axSpA N = 418 P
Female sex, % 506 37.4 54.5 33.7 <0.001
Age, years 506 40.2 (11.0) 39.5 (11.1) 40.4 (11.0) 0.52
Symptom duration, years 498 13.3 (10.0) 10.0 (9.9) 14.0 (9.8) <0.001
HLA-B27 positive, % 452 79.2 71.6 80.7 0.09
BASDAI 427 4.3 (2.2) 4.6 (2.0) 4.2 (2.3) 0.26
ASDAS 408 2.8 (1.0) 2.8 (0.9) 2.8 (1.1) 0.74
CRP (mg/l), median (IQR) 423 8.0 (3.0; 11.0) 5.0 (2.0; 8.0) 8.0 (3.0; 12.0) 0.005
Elevated CRP, % 422 38.9 30.6 40.6 0.14
BASFI 433 3.0 (2.5) 2.8 (2.2) 3.1 (2.5) 0.71
BASMI 435 2.0 (1.9) 1.1 (1.4) 2.2 (2.0) <0.001
mSASSS median (IQR) 506 0.8 (0.0; 4.0) 0.0 (0.0; 1.0) 1.0 (0.0; 6.0) <0.001
mean (SD) 5.8 (11.8) 0.9 (1.5) 6.8 (12.7)
Syndesmophytes present, % 506 30.6 9.1 35.2 <0.001
EQ-5D 429 64.6 (21.0) 61.5 (18.4) 65.2 (21.4) 0.07
Current peripheral arthritis, % 440 30.0 36.8 28.6 0.17
Current enthesitis, % 443 56.4 68.4 54.0 0.02
On csDMARD, % 506 16.0 14.8 16.3 0.87
On NSAIDs, % 401 84.3 80.6 85.1 0.37
On TNFi, % 506 33.4 19.3 36.4 0.002
Current smokers, % 427 37.2 29.7 38.8 0.15
BMI 431 25.2 (4.3) 24.9 (4.5) 25.3 (4.3) 0.48
Number exercise sessions per week, median (IQR) 423 2.0 (0.0; 2.0) 2.0 (0.0; 2.0) 2.0 (0.0; 3.0) 0.08
Patients with different number of radiographic intervals, % 506 0.96
1 interval 69.8 68.2 70.1
2 intervals 19.8 20.4 19.6
3 intervals 8.1 9.1 7.9
4 intervals 2.2 2.3 2.1
5 intervals 0.2 0.0 0.2
Length of radiographic interval 506 2.2 (0.5) 2.3 (0.6) 2.2 (0.5) 0.38
Values are the mean (SD), except where indicated otherwise. ASDAS = Ankylosing Spondylitis Disease Activity Score; BASDAI = Bath Ankylosing Spondylitis Disease
Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; BASMI = Bath Ankylosing Spondylitis Metrology Index; C-reactive protein (CRP) levels;
BMI = body mass index; csDMARD = conventional synthetic disease modifying antirheumatic drug; EQ-5D = EuroQol 5-domain; HLA-B27 = human leucocyte
antigen B27; MASES = Maastricht Ankylosing Spondylitis Enthesitis Score; modification refers to the inclusion of the plantar fascia in the count; nr-
axSpA = nonradiographic axial spondyloarthritis; NSAIDs = Nonsteroidal anti-inflammatory drugs; r-axSpA = radiographic axial spondyloarthritis; TNFi = Tumour
necrosis factor inhibitor.
https://doi.org/10.1371/journal.pone.0230268.t001
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When analysing the nr-axSpA group separately, a comparable point estimate of the effect
size of prior use of TNFi on a change in mSASSS�2 units was found after adjustment for base-
line mSASSS and sex, but, due to the small sample size, the effect did not achieve statistical sig-
nificance (OR 0.46, 95% CI 0.04; 5.43, p = 0.54). Baseline mSASSS was associated with an
enhanced radiographic progression in this model (OR 1.61, 95% CI 1.06; 2.44, p = 0.03).
Formation of new syndesmophytes
The proportion of patients with at least one syndesmophyte at baseline was higher in patients
with r-axSpA than in patients with nr-axSpA (35.2% vs. 9.1%, p<0.001). At least one new syn-
desmophyte was identified by both readers in 7/109 (6.4%) radiographic intervals in nr-axSpA
and in 102/616 (16.6%) intervals in r-axSpA after 2 years. The proportion of patients with�2
syndesmophytes per 2-year radiographic interval was 1/109 (0.9%) in nr-axSpA and 44/616
(7.1%) in r-axSpA. In the adjusted analyses, classification status as nr-axSpA was also associ-
ated with a lower odds for the formation of at least one new syndesmophyte (total effect: OR
0.45, 95% CI 0.22; 0.93, Table 3B). The direct effect of sacroiliac damage on spinal progression
in the mediation analysis–assessed by introducing the baseline presence of syndesmophytes as
a variable to the model, was not significant (Table 3D). In contrast, we found an important
effect size of its indirect impact, meaning that syndesmophytes usually do not appear until
Table 2. Baseline characteristics of all patients with r-axSpA and nr-axSpA at recruitment in SCQM.
Parameter nr-axSpA N = 431 r-axSpA N = 1155 P
Female sex, % 53.8 30.6 <0.001
Age, years 37.1 (10.8) 40.3 (11.3) <0.001
Symptom duration, years 8.8 (9.4) 15.0 (11.1) <0.001
HLA-B27 positive, % 73.1 81.5 <0.001
BASDAI 5.0 (2.2) 4.7 (2.2) 0.14
ASDAS 2.9 (0.9) 3.1 (1.1) 0.02
CRP (mg/l), median (IQR) 4.5 (2.0; 8.0) 8.0 (3.0; 15.0) <0.001
Elevated CRP, % 27.9 48.1 <0.001
BASFI 3.1 (2.4) 3.6 (2.6) <0.001
BASMI 1.3 (1.3) 2.5 (2.2) <0.001
EQ-5D 59.6 (20.9) 60.4 (22.4) 0.49
Current peripheral arthritis, % 38.7 31.6 0.01
Current enthesitis, % 73.5 65.1 0.002
On methotrexate, % 7.9 7.6 0.83
On sulfasalazine, % 5.3 4.8 070
On NSAIDs, % 89.5 88.6 0.64
On TNFi, % 13.9 22.8 0.002
Current smokers, % 31.1 40.6 0.001
BMI 24.7 (4.2) 25.3 (4.5) 0.01
Number exercise sessions per week, median (IQR) 2.0 (0.0; 4.0) 2.0 (0.0; 4.0) 0.92
Values are the mean (SD), except where indicated otherwise. ASDAS = Ankylosing Spondylitis Disease Activity
Score; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis
Functional Index; BASMI = Bath Ankylosing Spondylitis Metrology Index; C-reactive protein (CRP) levels; EQ-
5D = EuroQol 5-domain; HLA-B27 = human leucocyte antigen B27; MASES = Maastricht Ankylosing Spondylitis
Enthesitis Score; modification refers to the inclusion of the plantar fascia in the count; nr-axSpA = nonradiographic
axial spondyloarthritis; NSAIDs = Nonsteroidal anti-inflammatory drugs; r-axSpA = radiographic axial
spondyloarthritis; TNFi = Tumour necrosis factor inhibitor.
https://doi.org/10.1371/journal.pone.0230268.t002
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definite sacroiliac damage has occurred (OR 0.09, 95% 0.02; 0.36 for classification status as nr-
axSpA vs r-axSpA).
Prior use of TNFi was associated with reduced spinal progression in the subsequent 2-year
radiographic interval, when ASDAS was removed from this model (OR 0.49, 95% CI 0.31;
0.79). We then analysed longitudinal spinal radiographic progression in the subgroup of nr-
axSpA patients in a model adjusted for the baseline presence of syndesmophytes, sex and
ASDAS (89 intervals from 73 patients). A trend for an enhanced formation of syndesmophytes
over 2 years was found for both the presence of syndesmophytes at baseline and disease activity
as assessed by the ASDAS (OR 7.07; 95% CI 0.64; 78.5, and OR 3.49, 95% CI 0.68; 18.0,
respectively).
Fig 2. Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) for individual patients plotted as a function of duration
since symptom onset. A. Patients with r-axSpA. B. Patients with nr-axSpA.
https://doi.org/10.1371/journal.pone.0230268.g002
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Discussion
Our present study confirms that patients with nr-axSpA display at the group level a lower
radiographic spinal progression than patients with r-axSpA [4, 10]. It allowed a more detailed
analysis of the intricate relationship between radiographic damage of the sacroiliac joints and
of the spine. A previous analysis of the GESPIC cohort revealed an association of structural
damage in the sacroiliac joints with function and mobility of the spine, independently of
disease activity and structural damage in the spine [31]. As physical strain might lead to
Fig 3. 2-year progression in the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) depicted in a cumulative
probability plot. The change in mSASSS values from start to end of individual 2-years radiographic intervals is shown for r-axSpA
patients (circles) and for nr-axSpA patients (triangles).
https://doi.org/10.1371/journal.pone.0230268.g003
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inflammation and ultimately to osteoproliferation in spondyloarthritis [24], these changes in
function and mobility of the spine due to sacroiliac damage might theoretically increase syn-
desmophyte formation. However, our mediation analyses in this longitudinal study of patients
with nr-axSpA versus r-axSpA failed to demonstrate a statistically significant direct association
Table 3. Multivariable analysis for the identification of factors associated with spinal radiographic progression in
axSpA.
Progression defined as �2
mSASSS units in 2 years
Progression defined as�1
new syndesmophyte in 2
years
Variable OR 95% CI OR 95% CI
A B
Classification as nr-axSpA vs. r-axSpA (total effect) 0.33 0.13; 0.83 0.45 0.22; 0.93
ASDAS 1.35 1.09; 1.69 1.24 0.99; 1.57
Male sex 3.25 1.76; 6.00 2.65 1.51; 4.64
TNFi use prior to radiographic interval 0.92 0.57; 1.48 0.70 0.44; 1.11
Length of radiographic interval 1.73 0.90; 3.33 1.66 0.93; 2.99
C D
Classification as nr-axSpA vs. r-axSpA (direct effect) 0.40 0.14; 1.09 0.71 0.31; 1.62
BL mSASSS at start of each radiographic interval 1.07 1.05; 1.09 - -
BL syndesmophytes at start of each radiogr. interval - - 9.77 5.62; 17.0
ASDAS 1.35 1.04; 1.74 1.23 0.97; 1.57
Male sex 1.89 1.07; 3.36 1.38 0.73; 2.61
TNFi use prior to radiographic interval 0.70 0.42; 1.17 0.57 0.35; 0.92
Length of radiographic interval 1.83 0.96; 3.49 2.00 1.05; 3.80
Results from different multivariable models with spinal radiographic progression defined as an increase of �2
mSASSS units per 2 years (A, C) and progression defined as the formation of �1 syndesmophyte in 2 years (B, D).
Analyses performed in 725 radiographic intervals from 506 patients, according to Fig 1, either assessing the total or
the direct effect of classification criteria on spinal progression by ignoring or considering baseline spinal damage (A,
B or C,D, respectively). ASDAS = Ankylosing Spondylitis Disease Activity Score; CI = confidence interval;
mSASSS = modified Stoke Ankylosing Spondylitis Spine Score; nr-axSpA = nonradiographic axial spondyloarthritis;
OR = odds ratio; r-axSpA = radiographic axial spondyloarthritis; TNFi = Tumour necrosis factor inhibitor.
https://doi.org/10.1371/journal.pone.0230268.t003
Table 4. Multivariable analysis for the identification of factors associated with spinal radiographic progression in
axSpA (complete case analysis).
Progression defined as�2
mSASSS units in 2 years
Progression defined as �1 new
syndesmophyte in 2 years
Variable OR 95% CI OR 95% CI
A B
Classification as nr-axSpA vs. r-axSpA 0.20 0.06; 0.68 0.31 0.12; 0.80
ASDAS 1.39 1.10; 1.76 1.26 0.99; 1.61
Male sex 3.24 1.60; 6.55 3.00 1.53; 5.87
TNFi use prior to radiographic interval 1.02 0.61; 1.70 0.85 0.51; 1.41
Length of radiographic interval 1.57 0.75; 3.26 1.55 0.80; 3.01
Analysis performed in 602 radiographic intervals from 427 patients. ASDAS = Ankylosing Spondylitis Disease
Activity Score; BMI = Body Mass Index; CI = confidence interval; mSASSS = modified Stoke Ankylosing Spondylitis
Spine Score; nr-axSpA = nonradiographic axial spondyloarthritis; OR = odds ratio; r-axSpA = radiographic axial
spondyloarthritis; TNFi = Tumour necrosis factor inhibitor.
https://doi.org/10.1371/journal.pone.0230268.t004
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between sacroiliac damage and spinal structural changes, confirming results previously found
in GESPIC [10]. We found a relation between sacroiliac damage and the presence of a first
syndesmophyte, as spinal radiographic changes at baseline were virtually restricted to patients
already presenting with radiographic sacroiliac changes. Given that baseline spinal damage
represents a major predictor of further damage [9, 32], a phenomenon confirmed here, this
represents an indirect association between sacroiliac and future spinal structural changes. Data
from the French DESIR cohort, a prevalence cohort of early axSpA (<3 years) pointed in the
same direction. Within the population of patients fulfilling the imaging part of the ASAS clas-
sification, spinal progression was lowest in patients lacking definite sacroiliac damage, inter-
mediate in patients fulfilling the modified New York criteria but lacking bone marrow edema
on sacroiliac joint MRI and highest in patients having both definite sacroiliitis on X-rays and
active sacroiliitis on MRI [4].
Our results highlight the importance of differentiating between r-axSpA and nr-axSpA,
which is contrary to the current trend in clinical practice to lump these two entities together.
Several issues might have accelerated this trend. Sacroiliac joint scoring according to the modi-
fied New York classification criteria by local rheumatologists or radiologists in comparison to
central scoring efforts have not always been reliable, particularly with regard to grade 1 versus
2 sacroiliitis [33]. Moreover, from a clinical point of view, disease burden seems similar in nr-
axSpA compared to r-axSpA and both disease states are seen as part of a continuum, although
this has remained controversial since the publication of the ASAS classification criteria [34–
36]. However, recent latent class analyses—performed to avoid inappropriate circularity in
the diagnosis of axSpA—yielded several latent classes, indicative of subgroups, forming the
“Gestalt” of axSpA [37]. This latter study might suggest together with our current findings,
that there might be an axSpA subgroup of patients with a putatively genetically encoded
Table 5. Multivariable analysis for the identification of factors associated with spinal radiographic progression in
axSpA (model including additional variables).
A. Progression defined as�2
mSASSS units in 2 years
B. Progression defined as�1
new syndesmophyte in 2 years
Variable OR 95% CI OR 95% CI
Classification as nr-axSpA vs. r-axSpA 0.10 0.01; 0.70 0.21 0.05; 0.87
ASDAS 1.43 1.04; 1.97 1.32 0.96; 1.181
Male sex 5.54 2.22; 13.8 3.76 1.67; 8.47
TNFi use prior to radiographic interval 0.83 0.44; 1.57 0.68 0.36; 1.31
Length of radiographic interval 1.27 0.56; 2.88 1.71 0.74; 3.95
Disease duration (5 years) 1.31 1.13; 1.52 1.24 1.07; 1.43
Current smoking 0.90 0.49; 1.66 0.56 0.30; 1.06
HLA-B27 positivity 0.60 0.27; 1.32 0.81 0.36; 1.82
Number of exercise sessions per week 1.02 0.89; 1.17 0.86 0.74; 1.01
Peripheral arthritis 0.66 0.34; 1.28 0.58 0.30; 1.12
NSAIDs use at start of radiographic interval 0.85 0.40; 1.82 0.93 0.42; 2.06
BMI 25–30 (Ref. BMI<25) 1.49 0.82; 2.70 0.90 0.49; 1.65
BMI>30 (Ref. BMI<25) 1.38 0.60; 3.22 1.16 0.50; 2.73
Analysis performed in 447 radiographic intervals from 332 patients. ASDAS = Ankylosing Spondylitis Disease
Activity Score; BMI = Body Mass Index; CI = confidence interval; HLA-B27 = human leucocyte antigen B27;
mSASSS = modified Stoke Ankylosing Spondylitis Spine Score; nr-axSpA = nonradiographic axial spondyloarthritis;
NSAID = Nonsteroidal anti-inflammatory drug; OR = odds ratio; r-axSpA = radiographic axial spondyloarthritis;
TNFi = Tumour necrosis factor inhibitor.
https://doi.org/10.1371/journal.pone.0230268.t005
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tendency towards osteoproliferation which under certain conditions might evolve to r-axSpA
and later form syndesmophytes. This would be compatible with the presence within the nr-
axSpA population of a “pre-radiographic” subgroup that might be differentiated from the nr-
axSpA population that will never evolve to r-axSpA (“never-radiographic” axSpA or “true” nr-
axSpA), exemplified here by a relevant proportion of patients with 20–50 years of symptom
duration. The different progression rates from nr-axSpA to r-axSpA found in several previous
investigations might therefore be explained by differences in the proportion of patients with
“pre-radiographic” axSpA in the populations studied [38]. Future analyses, particularly genetic
studies, might help solving this conundrum.
Several additional arguments in favour of differentiating between r- and nr-axSpA from a
clinical and prognostic point of view cannot be disregarded. Firstly, the radiographic disease
state is, in the absence of an elevated C-reactive protein level, an important predictor of
response to treatment. Importantly, not all patients that require a biologic disease-modifying
anti-rheumatic drug (bDMARD) present with an elevated CRP. Only patients with an elevated
CRP or a sacroiliac joint MRI showing active inflammation have been shown to have a better
treatment response in comparison to placebo in nr-axSpA, which is mirrored in the current
ASAS treatment recommendations for axSpA [39]. Moreover, an increasing amount of data
has been published with regard to the fact the sacroiliac joint bone marrow edema of limited
extent is quite unspecific and can occur in other conditions, not related to axSpA [40, 41]. Sec-
ondly, deceleration of spinal radiographic progression increasingly becomes a treatment target
on its own in addition to the amelioration of clinical symptoms in axSpA, since it has consis-
tently been shown, that treatment with TNF inhibitors for at least 2 years can indeed retard
further syndesmophyte formation [11–14].
Our current findings indicate that this treatment target might be of different relevance in
nr- vs. r-axSpA, given that syndesmophyte formation is mainly restricted to the r-axSpA dis-
ease state. Finally, differentiation between nr- and r-axSpA by central scoring of pelvis radio-
graphs proved here to be reliable to efficiently discriminate between patients with or without
spinal progression. As a direct consequence of the current results, we have changed our prac-
tice of central scoring in SCQM, to immediately provide the treating rheumatologist feedback
with regard to classification status, SCQM being a real-life database used by hospital-based as
well as office-based rheumatologists primarily intended to allow treat-to-target strategies. It is
important to note that the cut-off of structural MRI lesions allowing reliable classification as
nr-axSpA vs. r-axSpA as a substitute for radiographs has already been established [42–44]. A
central MRI scoring for routine clinical practice might, however, be more difficult to
implement.
Overall spinal progression was very limited in our nr-axSpA group of rather long (10 years)
mean disease duration (0.16 mSASSS units over 2 years). Spinal progression in patients fulfill-
ing the ASAS classification criteria but lacking definite radiographic sacroiliitis in the DESIR
cohort was also very low (0.1 (±0.7) mSASSS units) [4]. A slightly higher spinal progression
(0.5 (±1.6) mSASSS units) was found over 2 years in nr-axSpA patients of the German GESPIC
cohort, including patients with a symptom duration of<5 years [10]. In contrast to SCQM
and DESIR, no part of this GESPIC population had been treated with bDMARDs during the
radiographic interval. We found a trend for lower mean spinal progression in patients treated
with TNFi compared to TNFi-naïve patients over 2 years (0.02 versus 0.21 mSASSS units,
respectively, p = 0.18). No significant impact of treatment with TNFi on spinal radiographic
progression was detected in the adjusted analysis of the nr-axSpA group, although the effect
size was comparable to the one found for the r-axSpA group. As overall spinal progression is
very limited in nr-axSpA, a potential influence of biologic treatment is very difficult to detect.
In RAPID-axSpA, a randomized controlled trial of certolizumab pegol in both AS and nr-
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axSpA, spinal progression over 4 years was similarly minimal in the nr-axSpA group (0.06
mSASSS units versus 0.98 mSASSS units in AS) [45]. In the absence of an untreated control
group, interpretation of the latter finding remains challenging.
Our study has some additional limitations, inherent to the observational nature of the
investigation. Selection bias cannot be ruled out, as spinal progression could only be analysed
in patients with an available radiograph set. However, baseline characteristics of the included
patients were comparable to those of the whole cohort. Moreover, we cannot exclude residual
confounding in the adjusted analyses. Information on concurrent inflammation on sacroiliac
MRI at the beginning of the radiographic interval might have improved the robustness of our
results. This information is, however, not available in SCQM, as data on prior sacroiliac
inflammation on MRI is collected from the treating rheumatologist for purposes of classifica-
tion, but the time-point of the examination largely remains unknown. Expecting, based on
previous publications [10], a rather limited radiographic progression in nr-axSpA, we chose
to score the radiographs in known chronological order. This has been shown to have a higher
sensitivity to change [28]. Moreover, scorers were blinded to all clinical data. The advent of
spinal progression assessment with low-dose CT opens new research opportunities [46, 47].
Conclusion
The formation of syndesmophytes in axSpA is mostly restricted to patients with structural
damage of the sacroiliac joints, further increasing the prognostic relevance of differentiating
between nr-axSpA and r-axSpA.
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